ENTPD3-specific CAR Regulatory T cells for Local Immune Control in T1D
Pieper, T.; Riet, T.; Saetzler, V.; McGovern, J.; Delsing, L.; Atkinson, M.; Lodie, T.; Jermutus, L.; Noyan, F.; Hust, M.; Kusmartseva, I.; Hagedorn, M.; Lieber, M.; Henschel, P.; Glaser, V.; Geffers, R.; Polansky-Biskup, J.; Yang, M.; Eiz-Vesper, B.; Bonifacius, A.; Martinez Llordella, M.; Bergerhoff, K.; Henry, L.; Penston, D.; Gavriil, A.; Grothier, T.; Nikolopoulou, E.; Demertzis, N.; Koullourou, V.; Cox, P.; Zarrouki, B.; Sini, M.; Pfeiff, J.; Matthiesen, I.; Hardtke-Wolenski, M.; Jaeckel, E.
Show abstract
Despite advances in Type 1 Diabetes (T1D) management such as hybrid closed loop systems, patients still face significant morbidity, reduced life expectancy, and impaired glucose regulation compared to healthy individuals or those with pancreas transplants. Here we developed beta cell-specific Chimeric Antigen Receptors (CAR) targeting the antigen ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) using a novel cell-based phage display methodology. ENTPD3 is highly expressed on beta cells of both early and progressed T1D patients. ENTPD3 CAR regulatory T cells (Tregs) homed, expanded and persisted in pancreatic islets in a T1D mouse model (NOD) and completely prevented disease progression. Human ENTPD3 CAR Tregs displayed a stable regulatory phenotype, strong activation, and suppression. Importantly, ENTPD3 CAR T cells recognised and were fully activated by human islets. This approach holds great promise as a durable treatment option for patients with prediabetes, new-onset diabetes, or those undergoing beta cell replacement therapy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An imbalance of naive and effector T-cell phenotypes in early type 1 diabetes across conventional and regulatory subsets 96%
- The immune profile of circulating autoreactive CD4 T cells is imprinted through tissue activation during autoimmune liver diseases 95%
- Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset 95%
Similar papers in this journal
- A microenvironment-driven, HLA-II-associated insulin neoantigen elicits persistent memory T cell activation in diabetes 96%
- High-Throughput and High-Dimensional Single Cell Analysis of Antigen-Specific CD8+ T cells 96%
- Stepwise chromatin and transcriptional acquisition of an intraepithelial lymphocyte program 94%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 94%
- Neonatal diabetes mutations disrupt a chromatin pioneering function that activates the human insulin gene 94%
- TIGER: The gene expression regulatory variation landscape of human pancreatic islets 94%
Similar papers in this journal
- Reduced function of the adaptor SH2B3 promotes T1D via altered γc cytokine-regulated, T cell intrinsic immune tolerance 96%
- Integrative proteogenomic analyses provide novel interpretations of type 1 diabetes risk loci through circulating proteins 93%
- Glucose-dependent miR-125b is a negative regulator of β-cell function 93%
Similar papers in this journal
- L-Phenylalanine is a metabolic checkpoint of human Th2 cells 93%
- Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics 93%
- Deep immune profiling reveals early-stage and highly coordinated immune responses in mild COVID-19 patients 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.